Microangiopathic hemolytic anemia pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 6: Line 6:
==Overview==
==Overview==
==Pathophysiology==
==Pathophysiology==
In diseases such as hemolytic uremic syndrome, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, as well as malignant hypertension, the endothelial layer of small vessels are damaged with resulting fibrin deposition and platelet aggregation.  
* It is thought that [[microangiopathic hemolytic anemia]] is mediated by endothelial injury, [[platelet]] activation, micro[[thrombi]] formation, intra-vascular [[hemolysis]] and [[thrombocytopenia]].
In all causes, the mechanism of MAHA is the formation of a [[fibrin]] mesh due to increased activity of the system of [[coagulation]].  
* In diseases such as [[hemolytic uremic syndrome]], [[disseminated intravascular coagulation]], [[thrombotic thrombocytopenic purpura]], as well as malignant [[hypertension]], the endothelial layer of small vessels are damaged with resulting [[fibrin]] deposition and [[platelet]] aggregation.  
* The mechanism of endothelial injury varies depending on the underlying cause. It results in [[platelet]]s aggregation and activation the [[coagulation]] cascade. There is the formation of a [[fibrin]] mesh due to increased activity of [[coagulation]] cascade.
* This results in the formation of micro[[thrombi]] in the [[blood vessel] and reduction of the caliber of the [[blood vessels]].
* The [[red blood cells]] are fragmented due to mechanical sheering by the micro[[thrombi]].  
===Microscopic Pathology===
===Microscopic Pathology===
The red blood cells are physically cut by these protein networks, and the fragments are identical to the schistocytes seen on light microscopy.
The [[red blood cell]]s are physically cut by these protein networks, and the fragments are identical to the [[schistocyte]]s seen on light microscopy.
 
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 21:07, 30 January 2021

Microangiopathic hemolytic anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Microangiopathic hemolytic anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Microangiopathic hemolytic anemia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Microangiopathic hemolytic anemia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Microangiopathic hemolytic anemia pathophysiology

on Microangiopathic hemolytic anemia pathophysiology

Microangiopathic hemolytic anemia pathophysiology in the news

Blogs on Microangiopathic hemolytic anemia pathophysiology

Directions to Hospitals Treating Microangiopathic hemolytic anemia

Risk calculators and risk factors for Microangiopathic hemolytic anemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pathophysiology

Microscopic Pathology

The red blood cells are physically cut by these protein networks, and the fragments are identical to the schistocytes seen on light microscopy.

References

Template:WH Template:WS